semaglutide cons tirzepatide pros and for weight loss A 72-week trial compared the two leading GLP Primary Care in Rochester and

30,31 In our study, significant reductions in AST, ALT, and GGT levels were observed across all treatment groups

A more recent and much larger multicenter, population-based study published yesterday in JAMA Ophthalmology has revealed an elevated inherent relative risk (incidence rate ratio, 1.32) of NAION for those exposed to semaglutide thats much smaller than the 4.28-fold hazard ratio (HR) found in a study published last summer.1 This was a retrospective study across 14 databases (six administrative claims and eight electronic health records)

But you may need regular follow-up appointments, so that your doctor can check your progress and adjust your treatment plan as needed

In phase 2 trials, discontinuation rates due to side effects ranged between 510% , which is considered acceptable for this drug class